FDA experts wave through Pfizer's copycat of an anemia med from Amgen, J&J, but a legal challenge still remains
Pfizer had no problem convincing an expert panel at the FDA that its biosimilar of Amgen’s blockbuster anemia med Epogen and Procrit, marketed by J …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.